Promising results have been observed for the GLP-1/GIP agonist LY3298176 in overweight or obese people with T2D, noting a weight loss between 0.9 and 11.3 kg in participants using the dual agent compared with 0.4 kg and 2.7 kg in those using placebo or dulaglutide respectively [52]
Through a gamification approach, residents are encouraged to contribute their insights, voice concerns, and collaborate on community development initiatives
Kim, H.H., Kim, D.H., Kim, M.H., Oh, M.H., Kim, S.R., Park, K.J., Lee, M.W., 2013
ValiSMythriRBJagathaBPadiadpuJRamanujanKSAndersenJKet alIntegrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinsons disease: a dynamic model
doi: 10.1017/S0007114510004447 58